5 promises AstraZeneca must keep now Pfizer's gone
This article was originally published in Scrip
You may also be interested in...
Tagrisso shines for AstraZeneca in the first quarter and the company is on track for approval of a fifth new cancer drug, in line with 2014 promises made by CEO Pascal Soriot when the company rejected takeover offers from Pfizer.
Last week, AstraZeneca's CEO Pascal Soriot was rumored to be preparing for a move to run Teva Pharmaceutical Industries. This week, he's rumored to be staying put. Scrip takes a look at the key moments in his tenure at the UK big pharma, and the progress on targets.
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.